Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
I-FP-CIT SPECT/CT was performed in response to the suspicion of atypical parkinsonian syndrome.
|
31524680 |
2019 |
Parkinsonian Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
<sup>123</sup>I-FP-CIT SPECT was performed at a single-center level on 370 individuals with PS, including 280 patients with Parkinson's disease (PD), 21 with multiple system atrophy-parkinsonian type (MSA-P), 41 with progressive supranuclear palsy (PSP) and 28 with corticobasal syndrome (CBS) (mean age 70.3 years, 47% female, mean disease duration at scan 1.4 year), as well as 208 age- and gender-matched control subjects.
|
31037416 |
2019 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
The utility of the combined use of <sup>123</sup>I-FP-CIT SPECT and neuromelanin MRI in differentiating Parkinson's disease from other parkinsonian syndromes.
|
29804474 |
2019 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
This study aims to investigate the patterns of striatal <sup>18</sup>F-FP-CIT uptake in patients with AD-related cognitive impairment (ADCI) with mild parkinsonism.
|
30980099 |
2019 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
<sup>18</sup>F-FP-CIT dopamine transporter PET findings in cirrhotic patients with parkinsonism.
|
28259768 |
2018 |
Parkinsonian Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To evaluate the value of I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane (I-FP-CIT) dopamine transporter single photon emission computed tomography (DAT-SPECT) to change management strategies of patients suspected of parkinsonism.
|
30153144 |
2018 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
123I-FP-CIT SPECT and MRI Findings in a Patient With Parkinsonism After Fenpyroximate Intoxication.
|
29629914 |
2018 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
A combination of cardiac <sup>123</sup>I-meta-iodobenzylguanidine scintigraphy and <sup>123</sup>I-FP-CIT single-photon emission computed tomography imaging, in addition to brain magnetic resonance imaging findings, helped to discriminate MSA-P from other sources of parkinsonism.
|
29783976 |
2018 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed at examining sensitivity of combined visual and semi-quantitative <sup>123</sup>I-FP-CIT SPECT analyses in a prospective cohort of subjects with DLB and degenerative parkinsonisms - Parkinson's disease (PD), multiple system atrophy (MSA), corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP) to determine prevalence and clinical significance of scans without evidence of dopaminergic deficit (SWEDD).
|
29406901 |
2018 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Dopamine transporter (DAT) imaging with [<sup>123</sup>I]FP-CIT (DaTSCAN) is a widely used diagnostic tool for Parkinsonism and dementia.
|
28382589 |
2017 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Usefulness of combining <sup>123</sup>I-FP-CIT-SPECT striatal asymmetry index and cardiac <sup>123</sup>I-metaiodobenzylguanidine scintigraphy examinations for diagnosis of parkinsonisms.
|
28477690 |
2017 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Utility of Follow-up Dopamine Transporter SPECT With 123I-FP-CIT in the Diagnostic Workup of Patients With Clinically Uncertain Parkinsonian Syndrome.
|
28574876 |
2017 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Analysis of Extrastriatal <sup>123</sup>I-FP-CIT Binding Contributes to the Differential Diagnosis of Parkinsonian Diseases.
|
27856628 |
2017 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
We enrolled eleven unrelated patients (8 F and 3 M) with clinical parkinsonism and normal [(123)I]FP-CIT SPECT.
|
25182701 |
2014 |
Parkinsonian Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We performed brain MRI and (123)I-FP-CIT SPECT in all and in 3 additional patients carrying the same mutation but without parkinsonism.
|
23412372 |
2013 |
Parkinsonian Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The parkinsonism was confirmed with (123)I-FP-CIT SCAN.
|
24076137 |
2013 |
Parkinsonian Disorders
|
0.100 |
Biomarker
|
group |
BEFREE |
Patients with mild parkinsonian symptoms, excellent response to low dosages of dopaminergic drugs and a reduced dopamine-transporter uptake in [(123)I] FP-CIT-SPECT might more commonly be GCH1 mutation carriers than has previously been supposed.
|
22030322 |
2012 |
Parkinsonian Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The authors studied three patients with parkinsonism carrying small expansions in the FMR1 gene (41-60 CGG) with [(123)I]β-CIT SPECT imaging.
|
20702130 |
2010 |
Parkinsonian Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The authors studied four patients with parkinsonism carrying the fragile X premutation using SPECT with ([23)I]FP-CIT.
|
16380622 |
2005 |